Analysis reveals circulating tumor cells predict recurrence in high-risk non-muscle invasive bladder cancer, suggesting improved patient management strategies.
The study aimed to explore the distribution of circulating tumor cells (CTCs), circulating tumor endothelial cells (CTECs), and their subtypes in non-cancer and bladder cancer individuals, focusing on their prognostic value in high-risk non-muscle invasive bladder cancer (NMIBC). Researchers analyzed 59 fresh peripheral blood samples using subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH). Samples were collected from healthy individuals (n = 18), patients with benign urinary conditions (n = 2), newly diagnosed bladder cancer patients (n = 20), and NMIBC patients after repeated transurethral resection of bladder tumor (R-TURBT) (n = 19). NMIBC patients had significantly higher total CTCs. In newly diagnosed bladder cancer patients, large CTCs constituted 58.8%. The most common karyotype was ≥ pentaploid CTCs (61.2%). In the non-cancer group, large CTCs constituted 83.0%, with ≥ pentaploid CTCs comprising 72.3% of aneuploid CTCs. For NMIBC patients after R-TURBT, those without recurrence had 16% small CTCs. Conversely, the recurrence group had 71% small CTCs, where tetraploid CTCs were predominant (40%). By performing logistic ridge repression, the ≥ pentaploid small CTC is noted as an important indicator of recurrence. The presence and proportion of small CTCs can serve as a prognostic marker in NMIBC patients following R-TURBT, potentially guiding patient management and surveillance strategies.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: